Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPT 2042 in Genetic Generalized Epilepsy with Absence Seizures
NCT06769659Phase 2Completed
- Sponsor
- NeuroPro Therapeutics
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NPT-2042 in genetic generalized epilepsy (GGE) and absence epilepsy (4 arms), sponsored by NeuroPro Therapeutics. Primary endpoint: Mean and median within subject difference in percent change from treatment period baseline of the frequency of absence seizures at 12 weeks. Started Mar 2025; status: completed.
02
Drugs
NPT-2042
03
Conditions
genetic generalized epilepsy (GGE)absence epilepsy
Beyond the preview
Go deeper on NCT06769659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769659.